I. Chow Hsu

I. Chow Hsu

Auto-generated profile, based on publicly available information

I. Chow Hsu

Department of Radiation Oncology, University of California San Francisco, San Francisco, CA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
IHI-Chow Hsu
I-Chow Hsu
KBKyounghwa Bae
Kyounghwa Bae
KSKatsuto Shinohara
Katsuto Shinohara
JPJean Pouliot
Jean Pouliot
JPJames Purdy
James Purdy
HSHoward Sandler
Howard Sandler

31 December 2008 in IEEE Transactions on Information Technology in Biomedicine
Verified
Journal Article
Closed access
RARon Alterovitz
Ron Alterovitz
KGKenneth Y. Goldberg
Kenneth Y. Goldberg
JPJean Pouliot
Jean Pouliot
IHI-Chow Hsu
I-Chow Hsu
Minimally invasive medical procedures such as biopsies, anesthesia drug injections, and brachytherapy cancer treatments require inserting a needle to a specific target inside soft tissues. This is difficult because needle insertion displaces and deforms the surrounding soft tissues causing the target to move during the procedure. To facilitate physician training and preoperative planning for these procedures, we develop a needle insertion motion planning system based on an interactive simulation of needle insertion in deformable tissues and numerical optimization to reduce placement error. We describe a 2-D physically based, dynamic simulation of needle insertion that uses a finite-element model of deformable soft tissues and models needle cutting and frictional forces along the needle shaft. The simulation offers guarantees on simulation stability for mesh modifications and achieves interactive, real-time performance on a standard PC. Using texture mapping, the simulation provides visualization comparable to ultrasound images that the physician would see during the procedure. We use the simulation as a component of a sensorless planning algorithm that uses numerical optimization to compute needle insertion offsets that compensate for tissue deformations. We apply the method to radioactive seed implantation during permanent seed prostate brachytherapy to minimize seed placement error.

2 February 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MAMekhail Anwar
Mekhail Anwar
VWVivian Weinberg
Vivian Weinberg
ACAlbert J Chang
Albert J Chang
IHI-Chow Hsu
I-Chow Hsu
MRMack RoachIII
Mack RoachIII
AGAlexander Gottschalk
Alexander Gottschalk
Patients with early stage prostate cancer have a variety of curative radiotherapy options, including conventionally-fractionated external beam radiotherapy (CF-EBRT) and hypofractionated stereotactic body radiotherapy (SBRT). Although results of CF-EBRT are well known, the use of SBRT for prostate cancer is a more recent development, and long-term follow-up is not yet available. However, rapid post-treatment PSA decline and low PSA nadir have been linked to improved clinical outcomes. The purpose of this study was to compare the PSA kinetics between CF-EBRT and SBRT in newly diagnosed localized prostate cancer. 75 patients with low to low-intermediate risk prostate cancer (T1-T2; GS 3 + 3, PSA < 20 or 3 + 4, PSA < 15) treated without hormones with CF-EBRT (>70.2 Gy, <76 Gy) to the prostate only, were identified from a prospectively collected cohort of patients treated at the University of California, San Francisco (1997–2012). Patients were excluded if they failed therapy by the Phoenix definition or had less than 1 year of follow-up or <3 PSAs. 43 patients who were treated with SBRT to the prostate to 38 Gy in 4 daily fractions also met the same criteria. PSA nadir and rate of change in PSA over time (slope) were calculated from the completion of RT to 1, 2 and 3 years post-RT. The median PSA nadir and slope for CF-EBRT was 1.00, 0.72 and 0.60 ng/ml and -0.09, -0.04, -0.02 ng/ml/month, respectively, for durations of 1, 2 and 3 years post RT. Similarly, for SBRT, the median PSA nadirs and slopes were 0.70, 0.40, 0.24 ng and -0.09, -0.06, -0.05 ng/ml/month, respectively. The PSA slope for SBRT was greater than CF-EBRT (p < 0.05) at 2 and 3 years following RT, although similar during the first year. Similarly, PSA nadir was significantly lower for SBRT when compared to EBRT for years 2 and 3 (p < 0.005). Patients treated with SBRT experienced a lower PSA nadir and greater rate of decline in PSA 2 and 3 years following completion of RT than with CF-EBRT, consistent with delivery of a higher bioequivalent dose. Although follow-up for SBRT is limited, the improved PSA kinetics over CF-EBRT are promising for improved biochemical control.

1 August 2015 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
CTChristopher L. Tinkle
Christopher L. Tinkle
VWVivian Weinberg
Vivian Weinberg
LCLee-May Chen
Lee-May Chen
RLRamey Littell
Ramey Littell
JCJ. Adam M. Cunha
J. Adam M. Cunha
IHI-Chow Hsu
I-Chow Hsu

21 January 2016 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MAMekhail Anwar
Mekhail Anwar
VWVivian Weinberg
Vivian Weinberg
ZSZachary Seymour
Zachary Seymour
IHI. Joe Hsu
I. Joe Hsu
MRMack Roach
Mack Roach
AGAlex R. Gottschalk
Alex R. Gottschalk
Treatment of intermediate and high-risk prostate cancer with a high BED has been shown to increase recurrence free survival (RFS). While high dose rate (HDR) brachytherapy, given as a boost is effective in delivering a high BED, many patients are not candidates for the procedure or wish to avoid an invasive procedure. We evaluated the use of stereotactic body radiotherapy (SBRT) as a boost, with dosimetry modeled after HDR-boost. Fifty patients were treated with two fractions of SBRT (9.5-10.5 Gy/fraction) after 45 Gy external-beam radiotherapy, with 48 eligible for analysis at a median follow-up of 42.7 months. The Kaplan-Meier estimates of biochemical control post-radiation therapy (95 % Confidence Interval) at 3, 4 and 5 years were 95 % (81–99 %), 90 % (72–97 %) and 90 % (72–97 %), respectively (not counting 2 patients with a PSA bounce as failures). RFS (defined as disease recurrence or death) estimates at 3, 4 and 5 years were 92 % (77–97 %), 88 % (69–95 %) and 83 % (62–93 %) if patients with PSA bounces are not counted as failures, and were 90 % (75–96 %), 85 % (67–94 %) and 75 % (53–88 %) if they were. The median time to PSA nadir was 26.2 months (range 5.8–82.9 months), with a median PSA nadir of 0.05 ng/mL (range <0.01–1.99 ng/mL). 2 patients had a “benign PSA bounce”, and 4 patients recurred with radiographic evidence of recurrence beyond the RT fields. Treatment was well tolerated with no acute G3 or higher GI or GU toxicity and only a single G3 late GU toxicity of urinary obstruction. SBRT boost is well-tolerated for intermediate and high-risk prostate cancer patients with good biochemical outcomes and low toxicity.

1 January 2014 in Practical Radiation Oncology
Verified
Journal Article
Closed access
IHI-Chow Hsu
I-Chow Hsu
DHDaniel Hunt
Daniel Hunt
WSWilliam Straube
William Straube
JPJean Pouliot
Jean Pouliot
ACAdam Cunha
Adam Cunha
HSHoward Sandler
Howard Sandler